NOXXON will participate in banking and investor conferences in January and February 2022


News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.

BERLIN – (BUSINESS WIRE) – Regulatory news:

NOXXON Pharma SA (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Aram Mangasarian, CEO of NOXXON, and Bryan Jennings, CFO of NOXXON, will attend and be available for meetings at several banking and investor conferences in early 2022.

LifeSci Partners Corporate Access Event, January 5-7, 2022, digital event

LifeSci Partners’ business access event will feature more than 200 innovative, publicly traded and private biotechnology, medical technology, pharmaceuticals, life sciences and digital health companies from around the world. The event will feature one-to-one meetings with the company’s management teams and panel discussions featuring KOLs, CEOs, specialist investors and health experts highlighting the most hot topics. relevant impacting the life sciences industry today. The NOXXON team will be available for meetings. Registration for the event is mandatory.

HC Wainwright BIOCONNECT virtual conference, January 10-13, 2022, digital event

BIOCONNECT hosted by HC Wainwright aims to connect life science companies with a diverse list of investors. NOXXON’s corporate video presentation will be available on demand starting January 10 at 7:00 a.m.ET. The team welcomes meetings with the investment community during the conference. Registration for the event is mandatory.

BIOMED EVENT 2022, January 26, 2022, Paris, France

The 7th edition of BIOMED EVENT organized by INVEST SECURITIES, will welcome numerous listed European biotechnology / medtech companies and institutional investors. The CEO of NOXXON will be available for individual and group meetings throughout the day. Registration for the event is mandatory.

LSX World Congress, February 8-9, 2022, London, UK or February 14-25, 2022, digital event

The 8th LSX World Congress will bring together founders and CEOs of innovative start-ups to large pharmaceutical companies and aims to provide a platform for companies to share their cutting-edge research and technologies. The congress offers an individual partnership, linking the c suite of the biotechnology, health technologies and medical technologies industry with the most active investors in the sector, the BD&L pharmaceutical and health technology teams, the leaders of leading R&D, KOLs and service companies driving the industry forward. . NOXXON’s in-person or virtual participation will be determined by the conditions imposed by the pandemic. More information about the event can be found here.


NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing the chemokines in TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and allow greater therapeutic impact. NOXXON’s main program, NOX-A12, provided final first-line data from a combined trial of Keytruda® in patients with metastatic colorectal and pancreatic cancer, published at the ESMO conference in September 2020 and July 2021 , the company announced its Phase 2 study, OPTIMUS, to further assess the safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as a second-line treatment in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in patients with newly diagnosed brain cancer who will not clinically benefit from standard chemotherapy, provided interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The Company’s second clinical-stage active, NOX-E36, is a phase 2 TME active targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. More information is available at:

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit NOXXON on LinkedIn and Twitter.

About the GLORIA study

GLORIA (NCT04121455) is the phase 1/2 dose escalation study of NOXXON of NOX-A12 in combination with irradiation in patients with first-line glioblastoma (brain cancer) with a non-MGMT promoter. methylated (resistant to standard chemotherapy).

About the OPTIMUS study

OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm phase 2 study of NOX-A12 in combination with pembrolizumab and nanoliposomal irinotecan / 5-FU / leucovorin or gemcitabine / nab-paclitaxel in patients with ‘stable microsatellite metastatic pancreatic cancer.


Certain statements in this communication contain wording or terms that refer to future or future developments, as well as negations of such wordings or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication concerning the expected or future results of the business segments, financial indicators, changes in the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on such forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the inventory on the day of publication.


Aram Mangasarian, Ph.D.

Chief executive officer

+49 (0) 30 726247 0

[email protected]

Investor and media relations:

LifeSci Advisors

Guillaume de Renterghem

+41 (0) 76 735 01 31

[email protected]


Arthur Rusty

+33 (0) 1 44 71 00 15

[email protected]

Source: NOXXON Pharma SA


About Author

Comments are closed.